Invesco DB Commodity Index Tracking Fund vs Medtronic PLC — how do they compare? Invesco DB Commodity Index Tracking Fund trades at $32.8 (market cap $1.93B), while Medtronic PLC trades at $87.9 (market cap $109.38B). The key difference: Medtronic PLC is far larger — about 56.7× Invesco DB Commodity Index Tracking Fund's market cap, and Medtronic PLC pays a 3.37% dividend while Invesco DB Commodity Index Tracking Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Commodity Index Tracking Fund for 61 Days and Medtronic PLC for 63 Days on average.
| DBC | MDT | |
|---|---|---|
Market Cap | $1.93B | $109.38B |
Volume | 569,977 | 55,890,185 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $33.68 | $105.35 |
52-Week Low | $22.07 | $73.75 |
Typical Hold Time | 61 Days | 63 Days |
Enterprise Value | — | $128.71B |
Dividend Yield | — | 3.37% |
Signals from Pluang's Aura AI — not financial advice
DBC trades at $32.51, down 0.55% on the day, with a bullish technical signal from moving averages. The company reported $82.59M in revenue and $22.38M net income for 2024, showing improved profitability from 2023's loss. Cash flow from operations was strong at $431.54M, contributing to a healthy balance sheet with $1.28B in shareholder equity and minimal debt.
The outlook appears favorable with positive earnings momentum and robust operational cash flow. Key risks include revenue volatility, as seen in historical fluctuations, and dependence on commodity market conditions. Analyst sentiment is constructive given the bullish technical indicators and improved financial performance.
Medtronic (MDT) trades at $85.51, down 1.81% on the day, showing bearish technical signals despite strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters with Q3 2026 results pending, while maintaining robust profitability margins of 65% gross and 14% net. Recent news highlights the company's 49-year dividend growth streak and new product approvals, though technical indicators show selling pressure with the stock trading near support at $85.
MDT presents a compelling value opportunity with a 3.2% dividend yield and 14% upside to the $97.80 consensus target, though near-term technical weakness and increasing debt levels warrant caution. The company's consistent earnings beats and medical device market leadership support long-term growth, while regulatory approvals for new systems provide catalysts.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DBC is a diversified commodity ETF that tracks the DBIQ Optimum Yield Diversified Commodity Index. It invests in futures contracts for 14 heavily traded commodities, including crude oil, gold, and corn, while optimizing for yield and roll costs.
Read more on DBC →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →